Drs. Avery Posey and Dannielle Engle are the inaugural winners of the Lustgarten Foundation-AACR Career Development Awards for Pancreatic Cancer Research in Honor of Ruth Bader Ginsburg and John Lewis.
Drs. Jennifer Knox and Elizabeth Jaffee lead the PASS-01 trial using biomarkers and other measures to choose individualized treatment.
Dr. Tyler Jacks is one of the leading pancreatic cancer researchers. Read what he has to say about KRAS, organoids, and running a lab in a pandemic.
The Lustgarten Foundation announces two new pancreatic cancer research laboratories through respective partnerships with Dana-Farber Cancer Institute and Massachusetts Institute of Technology (MIT).
Brigitte Régnier found a treatment team that was using an unusual approach of giving chemoradiation before surgery for pancreatic cancer.
An international team of researchers led by Dr. David Tuveson has found that organoids can predict how pancreatic cancer patients will respond to different treatments.
The Foundation’s dedicated lab at Cold Spring Harbor Laboratory (CSHL) used organoid technology to find that pancreatic cancer cells reprogram gene enhancers to achieve the ability to spread. The research, appearing online on August 8, 2017, in Cell, provides strong evidence supporting this explanation of metastasis, which is the cause of most cancer deaths. Experiments…
With a median survival of only 6 months and a 5-year survival rate of about 8%, patients tend to be diagnosed when the disease has already spread to other parts of the body—this is one part of the problem. Another is that when treated with existing chemotherapy drugs, patients tend to benefit only slightly or…
Dr. Stillman has served as director of the Laboratory’s National Cancer Institute (NCI)-designated Cancer Center for 25 years, shepherding the Center through five highly successful renewals and a overseeing significant expansion. He will continue in his long-standing role as President & CEO of CSHL, as well as maintaining a research laboratory that focuses on DNA…
A woman’s treatment for non-operable pancreatic cancer at Memorial Sloan Kettering includes FOLFIRINOX and stereotactic body radiation therapy.